A+ R A-

Novel Treatment Approaches, Treatment of Advanced Disease

Please select from the following list of abstracts, representing the presentations given in Kos 2007 (IWWM-4) Session 3:

Proteomic Analysis In Waldenstrom Macroglobulinemia. I. Ghobrial

The gene expression signature of clonal cells from Waldenstrom's Macroglobulinemia: differences and commonalities with the normal cell counterpart and other related lymphoproliferative disorders. Gutierrez N.C., Ocio E.M., Delgado M., de las Rivas J., Ferminan E., Martin-Jimenez P., Arcos M.J., Hernandez J.M., Garcia-Sanz R., San Miguel J.F.

Gene expression profiling of Waldenstrom's Macroglobulinemia reveals genes that may be related to disease pathogenesis. Hatjiharissi E., Zhan F., Adamia, S., Ciccarelli B.T., Cao Y., Xu, L., Hu H., Hunter Z.R., Patterson J.R., Ghobrial I.M., Barlogie B., Shaughnessy JD Jr., Treon SP

Novel splice variant transcript of Siva in Waldenstrom's Macroglobulinemia. Hatjiharissi E., Adamia S., Cao Y., Ciccarelli BT., Xu L., Treon SP

Aberrant post-transcriptional regulation of TNF family members and their adaptor molecules essential to B-cell growth and survival in Waldenstrom's Macroglobulinemia. Adamia S., Xu L., Hatjiharissi E., Ciccarelli BT., Cao Y., Sacco A., Hunter ZR., Patterson CJ., Treon SP

The functional role of CD27-CD70 interactions in Waldenstrom's Macroglobulinemia. Ciccarelli BT., Hatjiharissi E., Ho AW, Branagan AR, Hunter ZR, Adamia S., Leleu X., Xu L., O'Connor KE, Manning RJ, Santos DD, Patterson CJ, Soumerai JD, Munshi NC, McEarchern JA, Grewal IS, Treon SP

Serum concentrations of angiogenic cytokines in Waldenstrom's Macroglobulinemia: The ratio of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity. Anagnostopoulos A., Eleftherakis-Papaiakovou V., Zervas K., Kastritis E., Tsionos K., Bamias A., Dimopoulos M.A., Terpos E.

Use of the immunomodulators thalidomide and lenalidomide to augment rituximab clinical activity in Waldenstrom's Macroglobulinemia. Soumerai J., Branagan A., Hunter Z., Patterson C., Hatjiharissi E., Treon S.

Allogeneic stem cell transplantation (ALLO-SCT) in Waldenstrom's Macroglobulinaemia (WM). An analysis of 106 cases from the european bone marrow registry (EBMT). C. Kyriakou, C. Canals, G. Taghipour, JJ. Cornelissen, R. Willemze, G. Socie, K. Thompson, H. Greinix, JL. Harousseau, N. Ifrah, J. Kienast, R. Hamladji, M. Kazmi, P. Jacobs, A. Sureda, N. Schmitz

Increased incidence of disease transformation and development of MDS/AML in Waldenstrom's Macroglobulinemia (WM) patients treated with nucleoside analogues. Xavier Leleu, Robert Manning, Jacob Soumerai, Zachary R. Hunter, Anne-Sophie Moreau, Evdoxia Hatjiharissi, Aldo Roccaro, Antonio Sacco, Sophia Adamia, Christopher J. Patterson, Irene M. Ghobrial, Steven P. Treon

Clinical Profile And Treatment Outcome In 103 Patients With AL Amyloidosis Associated With IgM Paraproteinaemia. Wechalekar AD, Gillmore JD, Lachmann HJ, Offer M, Hawkins PN

Resveratrol exerts antiproliferative effect and induces apoptosis in Waldenström's Macroglobulinemia. Roccaro A.M., Leleu X., Moreau A.S., Patterson C.J., Xu L., Jia X., Ngo H., Sacco A., Cao J., Ciccarelli B., Manning R., Adamia S., Hatjharissi E., Russo D., Vacca A., Dammacco F., Ghobrial I.M., Treon S.P.

Genomic mutations in the April/Taci/Traf pathway in Waldenstrom'as Macroglobulinemia. Hunter Z.R., Leleu X., Adamia S., Hatjiharissi E., Xu L., Ciccarelli B., Ioakimidis L., Moreau A.S., O'Connor K.E., Soumerai J., Patterson C., Hamilton S., Verselis S., Fox E.A., Treon S.P.